Document:

Exhibit 10.15

 

INVESTMENT AGREEMENT

 

This Investment Agreement
(this “Agreement”) is made and entered as of April 16, 2013 (the “Effective Date”) by and
between Lightlake Therapeutics Inc., a Nevada corporation (the “Company”), and Potomac Construction Limited
(the “Investor”).

 

WHEREAS, the Company is developing a
naloxone hydrochloride nasal spray for the emergency reversal of heroin or opioid overdose, which naloxone hydrochloride nasal
spray is expected to enter into an initial trial during H1 2013 that is being sponsored by the National Institutes of Health
(the “Product”);

 

WHEREAS, the Investor
has agreed to invest Six Hundred Thousand Dollars (US$600,000.00) to fund the research, development, marketing, and any other commercialization
activities connected to the Product (the “Investment”); and

.

WHEREAS, the Company
has agreed to assign the Investor the right to receive a certain amount of the financial return produced by the Product;

 

NOW THEREFORE, with
reference to the foregoing facts, the Company and the Investor agree as follows:

 

		1.	Interest Assignment.

 

1.1         The Company hereby
agrees to assign the Investor the right to receive, pro rata, six percent (6%) of the net profit generated from the Product in
perpetuity from the Effective Date (the “Interest”). “Net profit” shall be defined as the pre-tax
profits generated from the Product after the deduction of all expenses incurred by and payments made by the Company in connection
with the Product, including but not limited to an allocation of Company overhead based on the proportionate time, expenses and
resources devoted by Company to Product-related activities, which allocation shall be determined in good faith by the Company (the
“Net Profit”).

 

		2.	Net Profit Audits, Updates, Distributions and Other Transactions.

 

2.1         The Company shall
provide the Investor with an annual audit of Net Profits (the “Audit”), which Audit shall be completed after
the end of each calendar year.  Notwithstanding the foregoing, this Paragraph 2.1 shall not be applicable until the Product
generates Net Profit.

 

2.2         After the end of
each quarter of the calendar year, the Company shall provide the Investor with a written or electronic update with respect to the
status of the Product. If the Product generates Net Profit, then the Company shall also provide the Investor with a written or
electronic statement of the estimated Net Profit represented by the Interest.

 

3.3         After the end of
each of the first three quarters of the calendar year, the Company shall distribute to the Investor eighty percent (80%) of such
calendar quarter’s Net Profits represented by the Interest, which amount shall be estimated in good faith by the Company.
Upon the completion of the Audit for such calendar year, the Company shall distribute to the Investor the Net Profits represented
by the Interest for the fourth quarter of the calendar year. In the event that the Audit for such calendar year determines the
Net Profits represented by the Interest for the first three quarters of the calendar year (the “Audited NP”)
to be greater than the estimated Net Profits represented by the Interest actually paid to the Investor for the first three calendar
quarters (the “Estimated NP”), then the Company shall distribute to the Investor the difference between the
Audited NP and the Estimated NP. In the event that the Audit for such calendar year determines the Audited NP to be less than the
Estimated NP, then the Company shall deduct the difference between the Estimated NP and the Audited NP from the distribution for
the fourth quarter of such calendar year and, if required, each following distribution until such amount is fully deducted.

 

    	 	 	 

     

    

 

3.4         In the event that
the Product is sold by the Company, then the Investor shall receive six percent (6%) of the net proceeds of such sale, pro rata,
and in the form of such net proceeds, after the deduction of all expenses and costs related to such sale. In the event that the
Company is sold, then the Company shall engage an independent financial or accounting firm to determine the fair value of the Company
which is directly attributable to the Product and the Investor shall receive six percent (6%) of such amount after the deduction
of all expenses and costs related to such sale. All other material transactions involving the Product not addressed herein shall
be addressed in good faith by the Company and the Investor.

 

		3.	Option to Exchange Interest for Common Stock.

 

3.1         If the Product is
not introduced to the market within twenty-four (24) months after the Effective Date, then the Investor shall have the option to
receive seven million five hundred thousand (7,500,000) shares of the Company’s common stock, par value $0.001 per share
(the “Shares”) in lieu of the Interest (the “Option”).

 

3.2         In the event that
Product is not approved for marketing within twenty-four (24) months after the Effective Date, then the Investor shall have sixty
(60) calendar days to provide written notice that the Investor intends to exercise the Option. The Investor shall waive their rights
to the Option if the Investor fails to provide sixty (60) calendar days written notice to the Company. If the Investor exercises
the option, then the Investor shall waive all rights to the Interest and receive fully paid and non-assessable Shares.

 

		4.	Representations and Warranties of the Company.

 

The Company represents
and warrants to the Purchaser that:

 

4.1         The Company is a public
company duly organized, validly existing and in good standing under the laws of Nevada and has all requisite power and authority
to own, lease and operate its properties and assets and to carry on its business as now being conducted and as proposed to be conducted.

 

4.2         This Agreement has
been duly executed and delivered by the Company and constitutes a valid and legally binding obligation of the Company enforceable
against the Company in accordance with its terms, subject to the effect of bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance and other similar laws relating to or affecting creditors' rights generally, or the availability of
equitable remedies.

  

		5.	Representations, Warranties and Agreements of Investor.

 

The Investor represents
and warrants to, and agrees with, the Company as follows:

 

5.1         Acquisition for
Investment. In the event that the Investor exercises the Option and receives Shares, the Investor is acquiring the Shares solely
for its own account for the purpose of investment and not with a view to or for sale in connection with distribution. In the event
that the Investor exercises the Option and receives Shares, the Investor does not have a present intention to sell the Shares,
nor a present arrangement (whether or not legally binding) or intention to effect any distribution of the Shares to or through
any person or entity. The Investor acknowledges that it is able to bear the financial risks associated with an investment in the
Shares and in the Company and that it has been given full access to such records of the Company and the subsidiaries and to the
officers of the Company and the subsidiaries and received such information as it has deemed necessary or appropriate to conduct
its due diligence investigation and has sufficient knowledge and experience in investing in companies similar to the Company in
terms of the Company’s stage of development so as to be able to evaluate the risks and merits of its investment in the Company.

 

5.2         Information on
Investor. Investor is, and will be on the Effective Date, an “accredited investor,” as such term is defined
in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made
investments of a speculative nature and has purchased shares of United States publicly-owned companies in private placements in
the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable
the Investor to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed
investment decision with respect to the proposed purchase, which represents a speculative investment. The Investor has the authority
and is duly and legally qualified to purchase and own the Shares. The Investor is able to bear the risk of such investment for
an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the
Investor is accurate.

 

    	 	 	 

     

    

 

5.3         Opportunities for
Additional Information. The Investor acknowledges that the Investor has not received any information from the Company regarding
this Investment. The Investor has the opportunity to ask questions of and receive answers from, or obtain additional information
from, the executive officers of the Company concerning the financial and other affairs of the Company. The Investor has not asked
such questions from the Company and is making its own decision without input and the Investor desires to invest in the Company.

 

5.4         No General Solicitation.
The Investor acknowledges that the Shares were not offered to the Investor by means of any form of general or public solicitation
or general advertising, or publicly disseminated advertisements or sales literature, including (i) any advertisement, article,
notice or other communication published in any newspaper, magazine, or similar media, or broadcast over television or radio, or
(ii) any seminar or meeting to which the Investor was invited by any of the foregoing means of communications.

 

5.5         Rule 144. The
Shares may not be offered for sale, sold, assigned or transferred unless such Shares are registered under the Shares Act or an
exemption from registration is available. The Investor acknowledges that the Investor is familiar with Rule 144 of the rules and
regulations of the Commission, as amended, promulgated pursuant to the Shares Act (“Rule 144”), and that such
person has been advised that Rule 144 permits resales only under certain circumstances.

 

5.6         No Guarantee of
Success. The Investor acknowledges that this is a speculative investment involving a high degree of risk and that there is
no guarantee of success or that the Investor will realize any gain from this investment, and the Investor could lose the total
amount of its investment.

 

5.7         Legends. The
Investor hereby agrees with the Company that the Shares will bear the following legend or one that is substantially similar to
the following legend:

 

THE SHARES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SHARES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SHARES LAWS AND NEITHER
SUCH SHARES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SHARES ACT AND APPLICABLE STATE SHARES LAWS OR (2) PURSUANT TO AN AVAILABLE EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SHARES ACT AND APPLICABLE STATE SHARES LAWS, IN WHICH CASE THE INVESTOR MUST, PRIOR TO
SUCH TRANSFER, FURNISH TO THE COMPANY AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH SHARES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED PURSUANT TO AN AVAILABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SHARES ACT AND APPLICABLE STATE SHARES LAWS.

 

		6.	Miscellaneous.

 

6.1         Notices.  All
notices, requests, demands and other communications (collectively, “Notices”) given pursuant to this Agreement
shall be in writing, and shall be delivered by personal service, courier, facsimile transmission or by United States first class,
registered or certified mail, postage prepaid, addressed to the party at the address set forth on the signature page to this Agreement.  Any
Notice, other than a Notice sent by registered or certified mail, shall be effective when received; a Notice sent by registered
or certified mail, postage prepaid return receipt requested, shall be effective on the earlier of when received or the fifth day
following deposit in the United States mails.  Any party may from time to time change its address for further Notices
hereunder by giving notice to the other party in the manner prescribed in this Section. Notwithstanding the foregoing, the Company
may send the information set forth in Paragraphs 2.1 and 2.2 via email.

 

    	 	 	 

     

    

 

6.2         Entire Agreement.  This
Agreement contains the sole and entire agreement and understanding of the parties with respect to the entire subject matter of
this Agreement, and any and all prior discussions, negotiations, commitments and understandings, whether oral or otherwise, related
to the subject matter of this Agreement are hereby merged herein.

 

6.3         Successors.  This
Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors, heirs
and personal representatives.

 

6.4         Waiver and Amendment.  No
provision of this Agreement may be waived unless in writing signed by all the parties to this Agreement, and waiver of any one
provision of this Agreement shall not be deemed to be a waiver of any other provision.  This Agreement may be amended
only by a written agreement executed by all of the parties to this Agreement.

 

6.4         Governing Law.  This
Agreement shall be construed in accordance with the laws of the State of Nevada without giving effect to the principles of conflicts
of law thereof.

 

6.5         Captions.  The
various captions of this Agreement are for reference only and shall not be considered or referred to in resolving questions of
interpretation of this Agreement.

 

6.6         Execution.  This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission
or by email delivery of a “pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “pdf”
signature page were an original thereof.

 

[Signature Page Follows]

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the
Company and the Investor have duly executed this Agreement as of the day and year first above written.

 

	LIGHTLAKE THERAPEUTICS INC.  	 	Potomac Construction Limited  
	 	 	 	 	 
	By:	/s/ Kevin Pollack	 	By:	/s/ Jerry Krueger
	 	 	 	 	 
	Its:	Chief Financial Officer	 	Its:	President

 

	Address: 86 Gloucester Place, Ground Floor Suite	Address:
	 	 
	London, W1U 6HP, UK	 
	 	 
	Attn: Dr. Roger Crystal	Attn:
	 	 
	Tel.: +44 7812 204 170	Tel:
	 	 
	Email: roger.crystal@lightlaketherapeutics.com	Email:Exhibit 10.16

 

 

 

October 15, 2014

 

Potomac Construction Limited

3089 Bathurst Street Suite 205A

Toronto, Ontario M6A 2A4 Canada

 

Re: Investment Agreement

 

Dear Potomac Construction Limited:

 

Reference is hereby made to that certain
Investment Agreement (the “Agreement”), dated as of April 16, 2013, between Lightlake Therapeutics Inc., a Nevada
corporation (the “Company”) and Potomac Construction Limited (“Investor”). This letter agreement
will confirm the understanding and agreement of the undersigned parties regarding the interpretation and application of certain
terms of the Agreement. Capitalized terms that are used but not defined herein have the meanings ascribed to them in the Agreement.

 

The Company is presently contemplating entering
into an agreement (the “Adapt Agreement”) with Adapt Pharma Operations Limited or its affiliate (as applicable,
“Adapt”) pursuant to which, inter alia (i) the Company will transfer to Adapt certain patent applications
claiming inventions associated with the Product and potentially other products containing naloxone for use in the treatment of
opioid overdoses, (ii) the Company will transfer or assign to Adapt certain existing inventories of product, materials and work
in process and certain contractual rights under contracts relating to the Company’s development of the Product, (iii) the
Company will exclusively license to Adapt (with the right to grant sublicenses) other current or future patents, as well as know-how
and other intellectual property for exploitation in connection with such products on a worldwide basis, (iv) Adapt, as consideration
for such transfers, assignments and licenses, shall pay the Company certain upfront and contingent milestone payments, as well
as royalties on its sales of products developed pursuant to the Adapt Agreement. The transactions contemplated by the Adapt Agreement
are referred to herein collectively as the “Adapt Transaction”.

 

In relation to the Adapt Transaction, the
Company and the Investor hereby agree as follows:

 

1.          With
respect to the Agreement, the definition of Net Profit shall be replaced as follows: “Net Profit” shall mean any
pre-tax revenue received by the Company that was derived from the sale of the Product less any and all expenses incurred by and
payments made by the Company in connection with the Product, including but not limited to an allocation of Company overhead based
on the proportionate time, expenses and resources devoted by the Company to Product-related activities, which allocation shall
be determined in good faith by the Company.

 

Lightlake Therapeutics Inc.

96-98 Baker Street First Floor London,
W1U 6TJ United Kingdom

Phone: 44 20 3617 8739

www.lightlaketherapeutics.com

 

     

     

    

 

2.          All
amounts the Investor may be entitled to receive in respect of proceeds received by the Company of the Adapt Transaction, pursuant
to the Adapt Agreement or otherwise shall be the responsibility and obligation solely of the Company or its successor. The Investor
agrees and covenants, for the benefit of the Company and Adapt, Adapt’s successors, assigns and sublicensees and each of
their respective shareholders, directors, officers and employees (the “Adapt Parties”), that it shall under
no circumstances seek payment or other compensation for any such amount directly from any Adapt Party or assert any claim against
any Adapt Party in relation to the Adapt Agreement or the Adapt Transaction.

 

3.          The
Company and the Investor agree that the Adapt Parties are express third party beneficiaries of the Investor’s covenants contained
in this letter agreement and may enforce the provisions hereof and that the foregoing is a material inducement to Adapt to enter
into the Adapt Agreement.

 

4.          This
letter agreement shall be governed by the laws of the State of New York, without regard to the conflicts of law provisions thereof.
No provision of this letter agreement shall be amended, waived or otherwise modified without the express prior written consent
of the Company, the Investor and Adapt. This letter agreement shall be binding on the parties hereto and their respective successors,
heirs and personal representatives.

 

5.          This
letter agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. This letter agreement may be executed by facsimile or electronically transmitted signatures and such
signatures shall be deemed to bind each party hereto as if they were original signatures.

 

Please confirm your agreement with the foregoing
by executing this letter agreement where indicated below.

 

	 	Sincerely,
	 	 
	 	LIGHTLAKE THERAPEUTICS INC.
	 	 
	 	By:	/s/ Kevin Pollack
	 	Name: Kevin Pollack
	 	Title:   CFO and Director

 

Accepted and agreed:

 

	POTOMAC CONSTRUCTION LIMITED	 
	 	 
	By:	/s/ Jerry Krueger	 
	Name: Jerry Krueger	 
	Title:   President	 

 

Lightlake Therapeutics Inc.

96-98 Baker Street First Floor London,
W1U 6TJ United Kingdom

Phone: 44 20 3617 8739

www.lightlaketherapeutics.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]